LUNGevity Foundation

Thank you for supporting, researching, volunteering, advocating, walking, fundraising, chairing, attending, caregiving, educating, and encouraging the lung cancer community. You are what make this community great. We are thankful for you! If you need support during the holiday season, please visit our online communities available 24/7. lungevity.org/support

"There are only four kinds of people in the world: those who have been caregivers, those who are caregivers, those who will be caregivers, and those who will need caregivers" - Rosalynn Carter Caregivers, we see you and we appreciate you. You are not alone. If you are looking for resources or support, please visit lungevity.org/caregivers Our next Caregiver Connection Virtual Meetup will be December 18, register now by visiting lungevity.org/events

LUNGevity is bringing together experts from MD Anderson Cancer Center, UT Southwestern Medical Center, and UT Health San Antonio to share valuable insights and helpful resources for people living with lung cancer and care partners. Each panel includes a multidisciplinary team of clinicians from all three hospitals, giving their perspectives on clinical advancements and quality of life strategies. There will also be time for audience questions. Cancer Support Community North Texas and LUNGevity are also sharing information about support programs and resources available to you and your family. You can join us virtually or at an in-person watch party. This event is free to attend but advance registration is required. https://brnw.ch/21wXL1g

Anyone with lungs can get lung cancer. Yvonne shares her story of being diagnosed with lung cancer four years ago. Her doctor listened to her symptoms and Yvonne wants to empower everyone to advocate for themselves. Help us raise awareness the final week of #LCAM. Share your story, start a fundraiser, or make an impact in your community. Visit LUNGevity.org/LCAM to get started today. Oncogene Cancer Research

“Today’s research is tomorrow’s cure. If we want to see continued breakthroughs and advancements in lung cancer, we must secure a strong pipeline of researchers dedicated to improving outcomes for people with lung cancer,” Upal Basu Roy, PhD, MPH, Executive Director of Research at LUNGevity Foundation. The 2025 awardees represent early-career investigators working on projects that address some of the most pressing needs in lung cancer today. Through these awards, LUNGevity continues to drive innovation and hope—empowering scientists to make discoveries that will change what it means to be diagnosed with lung cancer. LUNGevity is proud to announce the following recipients of our 2025 Translational Research Program Awards. Learn more about LUNGevity research by visiting lungevity.org/research EGFR Resisters Lung Cancer Initiative American Society for Radiation Oncology (ASTRO) Dana-Farber Cancer Institute Memorial Sloan Kettering Cancer Center Yale University UCLA Boston University School of Medicine MD Anderson Cancer Center Columbia University Joyce Ogidigo PhD Adam Grippin Lauren Kearney, MD MICHAEL OH Gavitt Woodard Esther Redín Resano Elliott Brea Jill Feldman

226,000 people will be diagnosed with lung cancer this year with a new diagnosis every 2.3 minutes. We are grateful to the lung cancer research community for their tireless effort to make lung cancer a treatable disease. As of August 2025, 98 different treatment approaches have been approved by the United States Food and Drug Administration for the treatment of lung cancer. Share the facts and raise awareness. Visit lungevity.org/LCAM for ideas on how you can make an impact in your community!

FDA approval alert: Sevabertinib — a new targeted therapy option for treating patients with HER2-mutant NSCLC — was granted accelerated approval on November 19, 2025 by the US Food and Drug Administration (FDA). This approval benefits patients with NSCLC who have been previously treated with HER2-targeted therapies, as well as patients who have received previous treatment that did not target HER2. Learn more: https://brnw.ch/21wXIzc.

We are grateful to Representatives Castor, Fitzpatrick, and Wasserman Schultz for their leadership in reintroducing the Increasing Access to Lung Cancer Screening Act. This legislation would ensure coverage for lung cancer screening across all types of insurance for everyone who is currently recommended, and it would eliminate prior authorization for screening those individuals. Additionally, it would authorize a study to help us better understand populations at elevated risk for lung cancer who are not included in the current guidelines, as well as a national awareness campaign on lung cancer and screening. The bill would also increase access to tobacco cessation services in Medicaid. LUNGevity is proud to support this key legislation that will help us improve early detection and save lives. Read our statement here: https://lnkd.in/gJeWDqGh